Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease

White leghorn chickens on five farms were given a bivalent Marek's disease (MD) vaccine consisting of turkey herpesvirus (HVT) and SB-1 (a nononcogenic MD virus); other chickens received only HVT. The farms had histories of "vaccination failures," presumably owing to an exceptionally virulent challenge MD virus. The bivalent vaccine uniformly protected chickens better than HVT alone between 12 and 16-20 weeks of age, when serious MD losses occurred. During that period, total mortality in groups given both viruses ranged from 0.39 to 1.26% (mean 0.86%), whereas that in HVT-vaccinated groups not exposed to SB-1 varied from 1.92 to 7.44% (mean 3.43%). Chickens in pens or rows with close contact to those given bivalent vaccine also had low MD mortality rates (0.46-1.06%, mean 0.77%), probably from the spread of SB-1.     

Marek's disease in field chickens: correlation between incidence of Marek's disease and nuclear-inclusion formation in the feather-follicle epithelium

The present study confirmed that Marek's disease (MD)-associated nuclear-inclusion (NI) formation in the feather-follicle epithelium (FFE) is related to mortality from MD; it also presented useful data on the epidemiology of MD in HVT-vaccinated field chickens. Incidence of NI formation in the FFE of chickens on six rearing farms varied greatly by age and flock, but most of the field flocks showed biphasic peaks of incidence of NI in chickens consisting of a small peak at an early age (usually at 2-4 weeks of age) and a large peak between 13 and 16 weeks of age. MD tended to occur in chickens over 20 weeks old, and almost all MD-affected chickens showed NI formation persistently in the FFE, usually between 13 and 20 weeks of age. Chickens that were healthy at the end of observation showed either transient NI formation, usually between 13 and 16 weeks of age, or no detectable NI formation. Incidence of NI formation in the FFE of chickens at 19-20 weeks of age was related to mortality from MD: chickens with NI formation had a MD mortality rate of 66.7%, whereas chickens without NI formation had MD mortality of only 0.8%.     

Protective immunity to infectious bronchitis in broilers vaccinated against Marek's disease either in ovo or at hatch and against infectious bronchitis at hatch

Two experiments were conducted using commercial broiler chickens to determine if Marek's disease (MD) vaccines HVT/SB-1 and HVT plus CVI-988 given either in ovo or at hatch adversely affected the efficacy of infectious bronchitis (IB) vaccines (Ark and Mass serotypes) given by eyedrop on the day of hatch. Nonvaccinated negative controls and controls that received only IB vaccines were included in each study. Birds were challenged with either infectious bronchitis virus (IBV) Mass-41 or IBV Ark-99 on either day 26 or 27 of age. Protection was assessed 5 days post-IBV challenged by virus isolation from the trachea. The day of hatch mean antibody titer to IBV was 12,668 +/- 4704 and 2503 +/- 3243 by enzyme-linked immunosorbent assay in experiments 1 and 2, respectively. In each study, nonvaccinated controls had a significantly higher (P < or = 0.05) incidence (88%-100%) of IBV challenge virus isolation than did controls vaccinated for IB but not for MD. Analysis of data from both studies showed that protection to IB in groups that received only IB vaccines at hatch ranged from 55.0% to 77.3%, whereas protection to IB in groups receiving both MD and IB vaccines ranged from 50.0% to 95.5%. In both experiments and within IBV challenge serotype, broilers given MD vaccines (in ovo or at hatch) and IB vaccines at hatch had protection rates to IBV challenges that were not significantly less (P < or = 0.05) than IB protection rates of groups that received only IB vaccines at hatch. Analysis of these data shows that administration of high-titered MD vaccines either in ovo or at hatch did not affect the efficacy of an IB vaccination (serotypes Ark and Mass) given by eyedrop at hatch.     

Efficacy and safety of a cell-culture live virus vaccine for hemorrhagic enteritis of turkeys: laboratory studies

Poults free from hemorrhagic enteritis (HE) antibody were vaccinated by gavage at 1 day or 2 weeks of age with a live HE vaccine virus that had been propagated in a Marek's disease (MD)-induced B-lymphoblastoid cell line of turkey origin. Vaccinated and unvaccinated poults were challenged with a virulent HE virus at various times postvaccination. One hundred tissue-culture-infectious doses of the vaccine virus per poult were sufficient to induce a serological response as well as to protect poults against HE lesions and mortality. Vaccinated poults were protected against the disease as early as 1 week and as late as 8 weeks PV. The vaccine was efficacious by several routes of application. The vaccine virus spread horizontally from vaccinated to contact-exposed poults, as indicated by seroconversion and resistance of contact-exposed poults to challenge. The vaccine had no detectable harmful effects on the humoral immune response to particulate antigens or on weight gain of vaccinated poults. The vaccine proved to be free from MD virus, as indicated by the absence of MD lesions and antibody in 8-week-old chickens inoculated intra-abdominally with the vaccine at hatching. These findings indicate that the cell-culture-propagated HE vaccine is efficacious and safe.     

Effects of strain of chickens and vaccination with turkey herpesvirus on Marek's disease and lymphoid leukosis in breeding stocks.

1. A total of 3236 females from eight meat-type strains, half of which were vaccinated for Marek's disease (MD), and 11,193 Leghorn females from ten strains, all vaccinated for MD, were adventitiously exposed to MD and lymphoid leukosis (LL) viruses and observed to 392 and 497 d of age, respectively. 2. In the meat-type birds, vaccination reduced total mortality from 43-4% to 27-1% and mortality due to MD from 16-4% to 5-4% but did not affect mortality and LL (2-9% and 3-4%). 3. In the vaccinated Leghorns total mortality was 11%, including 2-1% from MD and 1-2% from LL. 4. Significant differences between strains of chickens were found in total mortality, as well as in MD and LL mortality. 5. Strain by vaccination interaction was observed in total rearing and adult mortality, as well as in the MD mortality of adult meat-type females. 6. Leghorn strains with higher rate of egg production and meat-type strains with lower growth rate to have better viability.     

A comparison of the efficacy against Marek's disease of cell-free and cell-associated turkey herpesvirus vaccine.

One-day-old White Leghorn and broiler chicks with maternal antibody to turkey herpesvirus (HVT) were vaccinated with 300 or 1,000 plaque-forming units (PFU) of cell-free or cell-associated HVT vaccine and challenged with virulent Marek's disease virus (MDV) by contact exposure. Broiler chicks receiving 300 PFU of cell-associated HVT had a 3.3% incidence of MD lesions, whereas only 2.0% of those receiving 1,000 PFU had macroscopic lesions. Broiler chicks vaccinated with 300 PFU of cell-free vaccine had 6.8% gross lesions, and 0.67% of the birds receiving 1,000 PFU had MD lesions. Unvaccinated broiler chickens had a 28.3% incidence of MD lesions. Unvaccinated White Leghorn chickens had a 48.9% incidence of macroscopic lesions, whereas 5.4% of the birds receiving 300 PFU of cell-associated HVT had gross lesions, and 8.3% of the birds vaccinated with 1,000 PFU had lesions. In contrast, 6.7% of the chicks vaccinated with 300 PFU of cell-free HVT had MD lesions, and only 4.0% of those receiving 1,000 PFU of cell-free HVT had macroscopic lesions.     

The occurrence of Marek's disease in genetically different groups of chickens

The occurrence of Marek's disease was studied under laboratory conditions in four genetically different groups of chickens (Brown Leghorn, F1 hybrids of the CB x IA inbred lines, pullets of the paternal branch of the grandparent stock of the Hybro meat type, and final hybrids of the White Hisex layer type) after infection with the Georgia strain of Marek's disease (MD) virus, used in two doses (1600 and 16,000 PFU per one bird). MD was diagnosed on the basis of the occurrence of macroscopic tumours; when these tumours were absent in birds which had died within 105 days from infection, the dead bodies were subjected to microscopic examination (peripheral nerves, gonads, skin, bursa of Fabricius, thymus, spleen). The size of the parenterally administered dose of the virus had no significant effect on mortality, occurrence of tumours and the MD virus in any of the groups of chickens tested. However, there was a time shift in the mortality curve in chickens infected with a lower dose. The significantly highest occurrence of MD was recorded in BrL chickens (100%). A somewhat lower occurrence of MD was recorded in the Hisex White chickens (87.8%) and in the CB x IA hybrids (73.8%). However, the dead CB x IA chickens had a higher occurrence of tumours (96.6%) than the Hisex White chickens (77.1%). The lowest MD occurrence was recorded in the pullets of the Hybro meat type (25.5%). The organ most frequently affected by tumours after infection of the birds with the Georgia strain was the liver (24.1%).     

Pathogenesis of a Marek's disease virus mutant lacking vIL-8 in resistant and susceptible chickens

A homologue of interleukin-8, viral interleukin-8 (vIL-8) has been identified in the genome of Marek's disease virus (MDV). This protein attracts peripheral blood mononuclear cells in vitro although its role in the pathogenesis of Marek's disease (MD) is not known. P chickens, genetically susceptible to MD, and N chickens, genetically resistant to the disease, were inoculated with either RB1B MDVor RB1BvIL-8smGFP, a vIL8 knockout RB1B MDV, to assess the role of vIL8 in the pathogenesis of MD. The tumor incidence was highest in the P birds given the RBIB virus, where the incidence was 100%. Tumor incidence in N birds given RB1B was 41.5%. Thirty-one percent of the P birds given RB1BvIL-8smGFP developed tumors, and no N bird given RB1BvIL-8smGFP developed tumors. Histologically, the tumors from RB1B-inoculated birds were larger and more invasive and had a more homogeneous cellular composition than those from RB1BvIL-8smGFP-inoculated birds, which were best described as microtumors. These microtumors did not obliterate the normal architecture of the tissues, and in contrast to the RBIB tumors, moderate numbers of heterophils were admixed with the proliferating lymphocytes. Susceptible birds receiving RB1B had the highest viral titers throughout the study, followed by the resistant birds inoculated with RB1B. P and N birds receiving RB1BvIL-8smGFP virus had consistently lower levels of viremia than their RB1B-inoculated counterparts although virus could be recovered from the birds during all stages of MD. In addition, the RB1BvIL-8smGFP virus was detected in birds held in contact with the inoculated group, although no tumors developed in contact control birds. This result indicates that RB1BvIL-8smGFP replicates in vivo but not as well as RB1B and that vIL8 is not essential for the completion of the pathogenesis of MD.     

Compatibility of turkey herpesvirus-infectious bursal disease vector vaccine with Marek's disease rispens vaccine injected into day-old pullets

Mixtures of turkey herpesvirus (HVT) and Rispens poultry vaccines have been used worldwide for over 20 yr, mainly for vaccination of future layers and breeders. With increasing virulence of Marek's disease (MD) virus strains, vaccination strategies are evolving toward the use of vaccines combining HVT and Rispens. A single vaccination either in ovo or at 1 day of age with the HVT + infectious bursal disease (IBD) vector vaccine is efficient against IBD. However, with vaccination programs that include a hatchery administration of the HVT + IBD vaccine, additional protection against very virulent and very virulent-plus MD viruses is needed, especially for layers and breeders. This study looked at the combination of four commercially available Rispens vaccines with the HVT + IBD vector vaccine injected at 1 day of age. MD challenge tests that were superior to 90% in relative score in all the groups vaccinated with both vaccines showed that the mixture of HVT + IBD and Rispens vaccines had no effect on clinical protection against MD, and IBD challenge tests showed that the mixture of HVT + IBD and Rispens vaccines had no effect on clinical protection against IBD, which was equal to 100% protection in all the groups vaccinated with both vaccines.     

Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein.

Recombinant strains of herpesvirus of turkeys (HVT) were constructed that contain either the fusion protein gene or the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) inserted into a nonessential gene of HVT. Expression of the NDV antigens was regulated from a strong promoter element derived from the Rous sarcoma virus long terminal repeat. Recombinant HVT strains were stable and fully infectious in cell culture and in chickens. Chickens receiving a single intra-abdominal inoculation at 1 day of age with recombinant HVT expressing the NDV fusion protein had an immunological response and were protected (> 90%) against lethal intramuscular challenge at 28 days of age with the neurotropic velogenic NDV strain Texas GB. Recombinant HVT expressing the NDV hemagglutinin-neuraminidase provided partial protection (47%) against the same challenge. Chickens vaccinated with recombinant HVT vaccines had low levels of protection against NDV replication in the trachea when challenged ocularly. Recombinant HVT vaccines and the parent HVT strain provided similar levels of protection to chickens challenged with the very virulent RB1B strain of Marek's disease virus, indicating that insertion of foreign sequences into the HVT genome did not compromise the ability of HVT to protect against Marek's disease.     

雏鸡马立克氏病强毒感染后脂质过氧化物的含量变化

１日龄雏鸡马立克氏病强毒（ｖＭＤＶ）人工感染马立克氏病（ＭＤ）发病率６２％,ＭＤ死亡率３４％;脾脏、胸腺、法氏囊、心脏、肝脏、肾脏、性腺脂质氧化物（ＬＰＯ）含量高于（Ｐ＞０．０５）或显著高于健康对照雏鸡（Ｐ＜０．０５）。     

Antibody response of chickens to serotype 1, 2, or 3 Marek's disease vaccines based on ELISA with infected cells as antigen

An enzyme-linked immunosorbent assay (ELISA) was applied to evaluate the antibody response of commercial White Leghorn chickens to vaccination against Marek's disease (MD) at hatch (day 0) with serotype-1 (Rispens), -2 (SB-1), or -3 (turkey herpesvirus, HVT) vaccine virus and to challenge on day 21 with MD virus. Antigens for the test were whole chicken embryo fibroblast cells infected with Rispens, SB-1, or HVT. The chickens were progeny of stock that had been vaccinated with HVT, and on day 21 the nonvaccinated group had higher levels of maternal antibodies to HVT than to other antigens (P < 0.05). Only SB-1 vaccine had induced antibodies by day 21, and this was detected only against homologous antigens. On day 49, all three vaccines had induced higher levels of antibodies to homologous than to heterologous antigens. Marek's Disease virus (MDV) induced antibodies to all three antigens, but challenging vaccinated chicks did not significantly increase levels of antibodies on day 81 to any of the three antigens. It was concluded that an ELISA using whole cells as antigens would have potential value for monitoring the antibody response induced by MD vaccines and virulent MDV.     

Genetic resistance to Leukosis virus infection: effects on mortality and egg production in Leghorn hens

The influence of genotypic differences in resistance to infection from Lymphoid Leukosis (LL) on mortality and egg production was studied in three pairs of sublines. One subline of each pair had been selected for resistance and the other for susceptibility to infection. At 10 months of age, almost no hens with neutralising antibodies against LL were found in the resistant sublines, while in each susceptible subline more than 40% of the hens had LL antibodies. At 21 months of age, very few hens of the resistant sublines had group-specific (gs) antigen in their eggs. Susceptible sublines differed considerably in this respect, from 81% gs antigen-positive hens in one subline to 9% or no positive hens in the others. On the whole, the susceptible sublines had 6% higher mortality during the laying period (8 months) but the size of the difference was influenced by vaccination against Marek's disease (MD) and varied considerably between pairs of sublines. Significant interactions between strain and genotype of resistance to LL infection were observed for mortality from "other causes" in hens vaccinated against MD, as well as for mortality from "Leukosis" and from "MD" in non-vaccinated hens. The average rate of lay from 1 to 8 months was 8% lower in susceptible hens. In the subline with the highest frequency of eggs containing LL group-specific antigen in the albumen, the reduction of laying rate was twice as large as in the other susceptible sublines.     

Testing the immunogenicity of the dermal antigen in Marek's disease virus]

An experiment was performed to study the immunogenicity of the dermal antigen of Marek's disease virus, extracted from the skin of 30-day-old chickens, infected with Marek's disease virus on the first day of life. Three kinds of samples were tested: (1) dermal antigen centrifuged at 10 000 g per 0.5 h, (2) dermal antigen centrifugated at 10 000 g per 0.5 h and 100 000 g per 1 h, (3) dermal antigen treated like sample (2) and partly purified by DEAE-cellulose chromatography. Samples (1) and (2) were inoculated to two-day-old chickens and the vaccination was repeated, using complete Freund's adjuvant, 21 days later. Sample (3) was inoculated to two-day-old chickens with DEAE-dextran. All the three groups were challenged together with the controls (non-vaccinated chickens) on the seventh day after the first vaccination. A reduction of mortality was observed in the chickens vaccinated with and re-vaccinated with sample (1) (23.07%) and in the chickens vaccinated with sample (3) (30.76%). The chickens of the latter group were the last to start dying from Marek's disease--only after the 10th week of life. In the chickens which had been vaccinated and revaccinated with sample (2) the mortality was not reduced. The study is continued, with particular emphasis on the relationship of DEAE-dextran to protection against Marek's disease.     

Isolation and characterization of an adventitious avian leukosis virus isolated from commercial Marek's disease vaccines

Commercial Marek's disease (MD) vaccines produced by two manufacturers were tested for possible contamination with avian leukosis virus (ALV). Samples of MD vaccines manufactured by two companies (A and B) were received from a breeder company; samples were also received directly from vaccine company B. Using virus isolation tests, samples initially tested positive for subgroup E (endogenous) ALV. However, upon repassage, the vaccines also tested positive for exogenous ALV. The isolated exogenous ALV proved to be a subgroup A virus, as determined by flow cytometry using polyclonal chicken antibodies specific for various subgroups of ALV, and by DNA sequencing of the envelope glygoprotein (gp85). The exogenous ALV isolated from MD vaccines was inoculated in chickens from ADOL lines 15I(5) x 7(1) and 0 to determine its pathogenicity and compare it with that of Rous-associated-virus-1 (RAV-1), the prototype strain of ALV-A. Each chicken from each line was inoculated with approximately 10,000 infectious units of RAV-1 or the ALV-A isolated from vaccines termed B-39 virus at 7th day of embryonation. At hatch, and at 4, 8, and 16 wk of age, chickens were tested for viremia and cloacal shedding; chickens were also observed for ALV-induced tumors within 16 wk of age. Viremia and cloacal shedding results suggest that chickens from both lines were susceptible to infection with either virus. Within 16 wk of age, the proportion of ALV tumors induced by strain B-39 in line 0 and line 15I5 x 7(1) chickens was 0% and 12%, respectively, compared with 62% and 67% in chickens inoculated with RAV-1. The data indicate that commercial MD vaccines produced by two manufacturers were contaminated with endogenous subgroup E and an exogenous subgroup A ALV. Further, data from biological characterization suggest that the ALV-A isolated from commercial MD vaccines is of low oncogenicity, compared with that of RAV-1. GenBank accession numbers: The gp85 gene sequences of ALV isolated from commercial Marek's disease vaccines have been deposited in GenBank and assigned the following accession numbers: A46 subgroup A, DQ412726 ; B53 subgroup A, DQ412727; A46 subgroup E, DQ412728; B53 subgroup E, DQ412729.     

Marek's disease--characterization of the VUB-70 strain in vivo]

In the course of serial passaging of the strain of Marek's disease (MD) (VUB-70) in White Leghorns the author investigated the morbidity, mortality, development of the MD-specific changes, and the effect of sex on these indices, for the purpose of characterization of the biological properties of an isolated strain of MD in vivo. The incubation period lasted from 41 to 46 days p. inf. on the first day of life. Pullets showed greater sensitiveness towards infection not only through higher morbidity and mortality, but also due to a larger number of tumorous changes. In MD-positive animals the same proportion of macroscopic and microscopic changes was found. The average occurrence of Marek's disease amounted to 74.4 p. c. On the basis of the biological properties in vivo the VUB-70 strain was characterized as a medium pathogenic strain of the acute form of Marek's disease.     

FIELD TRIALS WITH LYOPHILISED HERPESVIRUS OF TURKEYS VACCINE AGAINST MAREK''S DISEASE IN LAYER AND BROILER REARING FLOCKS

The safety and immunogenicity of commercial lyophilised herpesvirus of turkeys (HVT) vaccine against Marek's disease (MD) was evaluated in 19 field trials involving 76,848 vaccinated and 87,590 control chickens. In the first series of 11 trials involving one commercial vaccine at a dose of 536 plaque forming units (PFU) there was a significant reduction in the incidence of MD (P less than 0.001) and in total mortality (P less than 0.001) from 0 to 18 weeks due to vaccination and the overall protection was 85.2%. In the second series of eight trials involving another commercial vaccine at a dose range of 1360 to 1900 PFU there was a significant reduction in the incidence of MD (P less than 0.001) from 0 to 18 weeks of age due to vaccination. The overall protection was 77.8%. In both series there was a significant difference in MD mortality between meat breeders and crossbred pullets (P less than 0.005) in response to vaccination. There was also a significant difference in total mortality from 0-6 weeks of age between the two series suggesting either differences in response to the two vaccines or differences in the vaccination technique. In a number of trials the incidence of MD was low in the controls, however, where MD incidence was above 2% in the controls protection usually exceeded 80%. It was concluded the vaccines were safe and efficacious and the degree of protection was comparable to that obtained by HVT vaccines described in other countries.     

Recent increase of Marek's disease in Korea related to the virulence increase of the virus

The incidence of Marek's disease (MD), an important neoplastic disease of chickens, suddenly increased in 1997 in Korea. Most MD cases of this country were detected in chickens over 20 wk of age. Five MD viruses were isolated from field flocks in which severe MD losses had occurred, and one of the viruses was studied to compare its pathotype with the prototype JM strain. The isolate KOMD-IC induced severe depression not only in body weight but also in relative bursal weight, and the depression by KOMD-IC was more severe than that induced by JM strain. In addition, the incidence of MD tumor caused by KOMD-IC was higher than that caused by the JM strain. The protective capacity of several MD vaccines was studied against challenge with KOMD-IC. The protective levels of several MD vaccines such as herpesvirus of turkeys (HVT), HVT plus SB1, and Rispens were usually lower against challenge with KOMD-IC than those challenged with JM strain, even if the chickens vaccinated with serotype 1 were not completely protected against challenge with KOMD-IC. The above results indicate that the virulence of KOMD-IC isolated recently was increased, and the increase of MD outbreak in Korea may be related to the virulence increase of the virus. Various MD vaccine programs were applied to reduce MD loss to a broiler breeder farm where severe MD loss had occurred. Serotype 1 vaccine could dramatically decrease the mortality due to MD, and the best results were obtained from the flocks vaccinated with bivalent vaccine of Rispens and HVT.     

Efficacy of narasin in the prevention of necrotic enteritis in broiler chickens

The efficacy of narasin in the control of necrotic enteritis (NE) was investigated in a floor pen study of 2000 broiler chickens using a Clostridium perfringens feed inoculum challenge model. Treatments were 1) nonmedicated, nonchallenged; 2) nonmedicated, challenged; 3) narasin, nonchallenged; 4) narasin, challenged. Narasin was administered at 70 ppm in the feed from day 0 to trial termination on day 41. Challenge inoculum contained approximately 1 x 10(8) colony-forming units CP/ml and was administered from day 14 to day 16. In the unmedicated groups, challenged birds had significantly (P < 0.05) lower mean body weight and reduced feed efficiency at day 21 and significantly (P < 0.01) higher cumulative NE mortality at day 41 compared with unchallenged. Similarly, among unmedicated birds, those challenged had a significantly (P < 0.01) higher mean NE score on day 17 and significantly (P < 0.05) higher mean huddling scores on days 15-17 than unchallenged. Among challenged birds, those fed narasin had significantly (P < 0.05) higher mean body weight and improved feed efficiency at days 21 and 41 and significantly (P < 0.01) lower cumulative NE mortality at day 41 than unmedicated. Similarly, among challenged birds, those receiving narasin had a lower mean NE score on day 17 (P > 0.05) and significantly (P < 0.05) lower huddling scores on days 16 and 17 than unmedicated. Coccidiosis lesion scores were zero for birds euthanatized from all treatment groups on day 17, suggesting that the beneficial effects of narasin were not due to prevention of coccidiosis. This study thus provides evidence that narasin is effective in the prevention of necrotic enteritis in broiler chickens.     

A longitudinal field study of mortality and Marek's disease in Norwegian and imported White Leghorns

High mortality during the first part of the laying period was observed in Norwegian White Leghorns during the period 1988–1992. A longitudinal field study with repeated measurement of cumulative mortality was undertaken in the period from January 1994 to January 1996 to investigate (1) the mortality and susceptibility to Marek's disease (MD) in the Norwegian strain (NB41) compared to two imported layers, (2) the effect of MD on the total cumulative mortality in the period from 16 to 32 weeks of age in White Leghorn flocks, and (3) the effect of MD as judged by repeated measurement of cumulative mortality in the same period. All five layer hatcheries and 67% of the pullet-rearing farms in Norway participated in the field study. The egg-production farms were sampled by convenience. Recordings for the whole period were completed for 169 flocks in 101 farms. The statistical analyses were performed using both a general fixed-effects linear model and a mixed model with repeated measurements, with total flock-level cumulative mortality and flock-level cumulative mortality in four-week intervals as outcome variables, respectively.

The overall cumulative flock-level incidence of MD was 12% (24% and 8% in NB41 and Lohmann White, respectively). MD was not recorded in any of the Shaver White flocks. A significant difference (p < 0.001) was found in (1) total cumulative mortality: 8.2% in the NB41 and 5.0% in the imported layers, and (2) ‘interval-specific' cumulative mortality: 0.36% in the NB41 and 0.15% in the imported birds. A strong relationship was also demonstrated between MD and repeated measurements of ‘interval-specific' cumulative mortality (p < 0.001) but not when cumulative mortality was used as an overall measure for the whole laying period (p = 0.11). The results from the repeated-measures analysis also indicated a stronger effect of MD on flock-level ‘interval-specific' cumulative mortality in the NB41 than in the imported hens. The different cumulative mortality and susceptibility to MD observed in the NB41, compared to the imported hens, shows that the farmers will be able to reduce their losses by replacing the NB41 strain with one of the imported strains.